Amova Asset Management Americas Inc. Purchases 78,753 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Amova Asset Management Americas Inc. raised its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.0% during the fourth quarter, HoldingsChannel reports. The fund owned 2,026,588 shares of the biotechnology company’s stock after acquiring an additional 78,753 shares during the quarter. Amova Asset Management Americas Inc. owned 0.07% of Arcturus Therapeutics worth $12,403,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ARCT. AQR Capital Management LLC bought a new position in Arcturus Therapeutics during the first quarter valued at $128,000. Millennium Management LLC bought a new position in Arcturus Therapeutics during the first quarter valued at $4,892,000. Goldman Sachs Group Inc. increased its position in Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after acquiring an additional 42,636 shares during the last quarter. Acadian Asset Management LLC bought a new position in Arcturus Therapeutics during the first quarter valued at $701,000. Finally, Strs Ohio bought a new position in Arcturus Therapeutics during the first quarter valued at $89,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $7.16 on Wednesday. The firm’s 50 day moving average price is $8.05 and its 200-day moving average price is $7.42. Arcturus Therapeutics Holdings Inc. has a 52-week low of $5.85 and a 52-week high of $24.17. The company has a market cap of $203.49 million, a PE ratio of -2.55 and a beta of 2.36.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. The firm had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARCT has been the topic of a number of analyst reports. B. Riley Financial initiated coverage on shares of Arcturus Therapeutics in a research report on Wednesday, March 18th. They set a “buy” rating and a $22.00 price objective on the stock. Citigroup cut their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings upgraded shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, April 21st. Finally, Piper Sandler cut their price objective on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.44.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.